Leadership Overview
Confluent has 4 executives leading key functions including strategy, operations, finance, and market development.
Driven by innovation, Confluent applies materials science to MedTech innovation, enabling customers to offer life-saving products through engineered solutions and manufacturing expertise.
Driven by innovation, Confluent applies materials science to MedTech innovation, enabling customers to offer life-saving products through engineered solutions and manufacturing expertise.
Leadership Roles at Confluent
Dean Schauer - Director, Chief Executive Officer and President
Dean Schauer, the Director, Chief Executive Officer and President at Confluent, directs the overarching corporate strategy and operational execution. Schauer guides the company's application of materials science to MedTech innovation, ensuring Confluent's engineered solutions address the most challenging design problems for OEM medical device customers. This leadership ensures the delivery of life-saving products by leveraging proprietary expertise in Nitinol processing, biomedical textile knitting, and specialty polymer laser treatment. Overseeing all global operations, the Chief Executive Officer and President drives the company's market position and financial performance. Dean Schauer's strategic vision is critical to maintaining Confluent's reputation for innovative materials science, engineering, and manufacturing, fostering partnerships with leading OEMs for complex applications like transcatheter heart valves and neurovascular implants. The Chief Executive Officer and President ensures alignment across all facilities in California, Rhode Island, Maine, Texas, Tennessee, and Costa Rica, solidifying Confluent's role as a trusted partner in the medical device community.
Matthew Eckl - Chief Financial Officer
Matthew Eckl, the Chief Financial Officer at Confluent, directs all financial planning, reporting, and strategic fiscal management for the organization. Eckl oversees the financial health of Confluent, ensuring robust resource allocation to support its MedTech innovation initiatives and the development of life-saving products. This involves managing budgets, forecasting financial performance, and securing capital to drive growth in areas such as Nitinol processing and biomedical textile manufacturing. Leading the finance department, the Chief Financial Officer ensures compliance with all regulatory requirements and optimizes financial strategies to enhance shareholder value. Matthew Eckl's expertise is crucial for maintaining Confluent's strong financial standing and supporting its partnerships with leading OEMs in the medical device community. The Chief Financial Officer plays a key part in evaluating investment opportunities and managing financial risks associated with complex applications like neurovascular implants and advanced smart catheters, contributing directly to the company's sustained success and market confidence.
Edward Pike - Chief Operating Officer
Edward Pike, the Chief Operating Officer at Confluent, manages the day-to-day operational activities and manufacturing processes across all global facilities. Pike ensures the efficient execution of Confluent's materials science and manufacturing expertise, which is critical to the function and value of demanding, high-growth medical device products. This role involves optimizing the processing of high purity Nitinol, the ultra-high density knitting of biomedical textiles, and the precision laser treatment of specialty polymers. Overseeing production and supply chain logistics, the Chief Operating Officer guarantees that Confluent's engineered solutions meet the rigorous standards required by OEM medical device customers for products such as transcatheter heart valves and neurovascular implants. Edward Pike's leadership drives operational excellence, supporting the company's proven track record in engineering and manufacturing. The Chief Operating Officer ensures seamless integration of operations across Confluent's diverse locations, including facilities in California, Rhode Island, Maine, Texas, Tennessee, and Costa Rica, reinforcing the company's commitment to delivering life-saving medical technologies.
John Gray - President
John Gray, the President at Confluent, drives strategic initiatives and market development, focusing on expanding Confluent's reach within the MedTech sector. Gray collaborates closely with the Chief Executive Officer and President to translate Confluent's materials science expertise into market-leading solutions for OEM medical device customers. This involves identifying new opportunities for engineered solutions in complex applications such as transcatheter heart valves, neurovascular implants, and advanced smart catheters. Leading market engagement and business development, the President ensures Confluent's proprietary capabilities in Nitinol processing, biomedical textile knitting, and specialty polymer laser treatment are effectively communicated and leveraged. John Gray's leadership strengthens Confluent's relationships with key industry players, reinforcing the company's position as a critical partner in delivering life-saving medical technologies. The President champions innovation and growth, ensuring Confluent's manufacturing and engineering prowess continues to meet the evolving demands of the global medical device community.
Explore Leadership Teams in Manufacturing
Headquartered in Glen Allen, Virginia, Owens & Minor is a distributor of national name-brand medical and surgical supplies and a healthcare supply-chain management company. With a diverse product and service offering and distribution centers throughout the United States. The company serves hospitals, integrated healthcare systems, alternate care locations, group purchasing organizations, and the federal government. Owens & Minor provides technology and consulting programs that improve inventory management and streamline logistics across the entire medical supply chain--from origin of product to patient bedside.
Company Leadership
AY
Edwards Lifesciences is a global medical technology company focused on developing innovative solutions for structural heart disease and critical care monitoring. The company is dedicated to improving patient outcomes through advanced technologies, clinical research, and close collaboration with healthcare professionals. Its mission centers on delivering life-changing therapies that address serious cardiovascular conditions, particularly those involving the hearts valves and structural components.
Company Leadership
MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The companys proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta,...
Company Leadership
DR
DM
WT
Established in 1969 and headquartered in Neenah, Wisconsin, TIDI Products provides infection-control products for hospitals, clinics, offices and other environments where infection control is critical. TIDIs single-use products range from table paper, sponges, and gauze to personal protection equipment such as protective eyewear, gowns, masks and gloves.
Company Leadership JR
MH
AZ
Frequently Asked Questions Regarding Confluent Top Executives and Leadership Team
